Natco Pharma Ltd. benchmarking: Perfomance to industry peers

Financial

	Natco Pharma	Jubilant Pharmova	Caplin Point Lab
Operational Metrics
Pharmaceutical Sector
Number of ANDA's Filed in USA	51.0 .	100.0 .	51.0 .
Number of ANDA's Approved By USFDA	41.0 .	62.0 .	38.0 .
Domestic Sales Growth - YoY	31.2 %	n/a	n/a
US DMF Filings	58.0 .	98.0 .	n/a
R&D as a % of Total Sales	9.1 %	0.18 %	3.52 %
Financials
5 yr Average ROE	15.58 %	7.82 %	19.84 %
5yr average Equity Multiplier	1.17	1.96	1.15
5yr Average Asset Turnover Ratio	0.48	0.61	0.68
5yr Avg Net Profit Margin	26.79 %	6.45 %	25.35 %
Price to Book	2.08	2.81	6.25
P/E	9.34	38.19	31.54
5yr Avg Cash Conversion Cycle	4.27 Days	-39.98 Days	70.68 Days
Inventory Days	91.91 Days	74.06 Days	66.07 Days
Days Receivable	93.3 Days	45.59 Days	110.7 Days
Days Payable	134.54 Days	149.89 Days	85.23 Days
5yr Average Interest Coverage Ratio	60.49	3.78	633.04
5yr Avg ROCE	19.09 %	8.15 %	24.45 %
5yr Avg Operating Profit Margin	34.0 %	16.76 %	31.52 %
5 yr average Debt to Equity	0.06	0.55	0.0
5yr CAGR Net Profit	33.73 %	0.08 %	17.23 %
5yr Average Return on Assets	13.46 %	4.12 %	17.23 %
Shareholdings
Promoter Holding	49.56 %	47.68 %	70.56 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.76 %	-3.0 %	1.68 %
Change in Mutual Fund Holding (3 Yrs)	-4.64 %	5.97 %	0.87 %

Business

	Natco Pharma	Jubilant Pharmova	Caplin Point Lab
Product Wise Break-Up	Product Wise Break-Up Formulations 88.7 Active Pharmaceutical Ingredient (API) 3.8 Crop Protection 2.5 0 Radiopharmaceuticals 0 Allergy therapy products 0 Active pharmaceutical ingredients 0 India Branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 0 Solid dosage formulations 0 Branded Generic 0 Generic 0 Others 5.0	Product Wise Break-Up Active Pharmaceutical Ingredient (API) 7.91 Crop Protection 0 Formulations 0 Radiopharmaceuticals 46.89 Life science chemicals 0 Solid dosage formulations 8.71 Nutritional products 0 Specialty intermediates 0 Contract Manufacturing 17.66 India branded pharmaceuticals 0.7 Generic 0 Branded Generic 0 Active Pharmaceutical Ingredient (API) 0 Anti-allergic 9.75 Contract Research and Development Services 7.87 Others 0.51	Product Wise Break-Up Active pharmaceutical ingredients 0 Crop Protection 0 Formulations 0 Radiopharmaceuticals 0 Life science chemicals 0 Solid dosage formulations 0 Nutritional products 0 Specialty intermediates 0 0 India Branded pharmaceuticals 0 Formulations 75.0 Branded Generics 25.0 Active Pharmaceutical Ingredient (API) 0 Allergy therapy products 0 0
Segment Break-Up	Segment Break-Up Pharmaceuticals 97.39 Agrochemicals 2.61 CDMO Sterile Injectables 0 Generics 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 0 Life Science Ingredients 0	Segment Break-Up CDMO Sterile Injectables 20.34 Allergy Immunotherapy 9.92 Proprietary Novel Drugs 0 Generics 8.6 Radiopharma 45.01 Pharmaceuticals 0 Agrochemicals 0 Drug discovery and development solutions 16.13 Life Science Ingredients 0	-
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Oncology 58.79 Others 41.21	-	-
Location Wise Break-Up	Location Wise Break-Up USA 71.37 Rest of the World 16.18 India 12.44 China 0 Americas and Europe 0 Africa 0 LATAM 0 Others 0.01	Location Wise Break-Up LATAM 0 Rest of the World 5.89 Americas and Europe 91.35 China 0 Africa 0 India 2.76 USA 0	Location Wise Break-Up Latin America 76.0 Rest of the World 0 Americas and Europe 0 China 0 Africa 6.0 India 0 USA 18.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 100.0 Agrochemicals 0 Generics 0 CDMO Sterile Injectables 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0	Operating Profit Break-Up CDMO Sterile Injectables 18.74 Allergy Immunotherapy 26.65 Proprietary Novel Drugs 0 Contract Research and Development 11.74 Generics 0 Radiopharma 42.87 Pharmaceuticals 0 Agrochemicals 0 Life Science Ingredients 0	-
Asset Break-Up	Asset Break-Up Pharmaceuticals 95.33 Agrochemicals 4.67 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0	Asset Break-Up Proprietary Novel Drugs 2.13 Contract Research and Development 13.26 Pharmaceuticals 0 Agrochemicals 0 Life Science Ingredients 0 Others 84.61	-

Natco Pharma Ltd.

Natco Pharma Ltd.

Financial

Business

SIGN UP FOR FREE